FIGURE 8:

Mice with podocyte deletion of IRE1α and anti-GBM nephritis exhibit podocyte loss and foot process effacement. (A) Representative electron micrographs showing mild foot-process widening in uninjected IRE1α^{flox/flox;Cre} (M Cre) and injected IRE1α^flox/flox;+ (M +) mice and greater widening in anti-GBM antibody–injected M Cre mice (24 h). (B) Quantification of images showing foot-process widening/effacement (N, number of animals). (C) Representative WT1 immunofluorescence images of mice with acute anti-GBM nephritis (24 h). Scale bar, 50 μm. (D) Quantification of WT1-positive cells shows that anti-GBM antibody treatment in M Cre mice resulted in a modest but significant loss of podocytes (*p = 0.027 anti-GBM vs. control in the M Cre groups). In M + mice, there was no significant decrease in podocytes after anti-GBM antibody.